|Bid||138.72 x 800|
|Ask||139.26 x 800|
|Day's Range||138.56 - 139.50|
|52 Week Range||118.62 - 148.99|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||25.73|
|Earnings Date||Jul 16, 2019|
|Forward Dividend & Yield||3.80 (2.69%)|
|1y Target Est||148.12|
Oklahoma is the first to go to trial with a case relying on nuisance laws normally invoked for minor property disputes involving things such as loud noises or bright lights. “It’s the first time this theory has actually gotten to trial in pharmaceutical litigation, so everybody will be watching to see if it works,” said Richard C. Ausness, a University of Kentucky law professor who monitors opioid litigation. Oklahoma Attorney General Mike Hunter claims J&J and Teva are liable for at least $10 billion in damages from the state’s two-decade surge in opioid addiction.
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.
FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes
Johnson & Johnson (JNJ) closed the most recent trading day at $138.76, moving +0.46% from the previous trading session.
Democratic Republic of Congo called on Wednesday for Merck's experimental Ebola vaccine to be fully licensed to facilitate its use in the Ebola-hit country, while saying Johnson & Johnson's rival drug would complicate matters. Both vaccines are experimental drugs that can be used under strictly controlled research protocols but Merck's has been used throughout the outbreak and has proven highly effective, the World Health Organization (WHO) says. Congolese Health Minister Oly Ilunga Kalenga told reporters in Geneva that the government would roll out a "geographic ring" vaccination strategy in the coming days.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
Medical Device company DePuy Synthes is eliminating 76 jobs in Chester County. A Worker Adjustment and Retraining Notification Act notice the orthopedic and neurosurgery products developer filed last week with the Pennsylvania Department of Labor and Industry stated its DePuy Synthes Sales Inc. unit will be eliminating its extremities sales organization in West Chester. Asked about the job reduction, DePuy Synthes issued a statment that read: "DePuy Synthes recently made a strategic decision to move away from a dedicated extremities sales force as part of an ongoing assessment of resource utilization and optimization, resulting in an overall reduction in positions.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
The trade war with China has reignited, and while the tech companies may be getting the headlines, export-oriented industrials have also felt immediate effects. China is an important market for heavy construction and agricultural equipment, and the imposition of protective tariffs has made a mark on the import-export trade.We’ll dive into TipRanks’ analyst database to look at two major industrial companies feeling the pain from China, as well as one strong defensive play to minimize the hurt on your portfolio. Caterpillar, Inc. (CAT – Research Report)Despite beating expectations in the China market earlier this year, Caterpillar now says it expects full-year China-sales results to come in flat at best. This is a serious setback, as Caterpillar makes 10% of its global sales to China. Combined with a drop in operating margin – reported at 18.5% last month, down from 19.7% one year ago – the company is facing a serious headwind in East Asia.Quoted in Canada’s Globe and Mail newspaper, five-star analyst Stephen Volkmann (Track Record & Ratings) noted both points, saying, “Caterpillar has most exposure to China in their construction industry business and that business was just a bit disappointing on revenue and margins.”Caterpillar stock has had a difficult time gaining traction in recent years, as its share price peaked in January 2018 and has been on an uneven downward slope since then. With the end of Q2 2019, the company moved to placate shareholders, by boosting the dividend 20% to $1.03 per share ($4.12 annualized), which increased the yield to a respectable 3.37%. Shares gained $4 in the next session but are down $17 since.While CAT is facing headwinds, the outlook is not entirely gloomy. Oppenheimer’s Noah Kaye (Track Record & Ratings) set a ‘Hold’ on the stock, but his comments acknowledge that the company has extensive resources: “We got much of what we were looking for from CAT’s Investor Day last week. The company provided an updated view on its structurally improved cross-cycle margin and cash flow metrics… We believe CAT’s O&E model has successfully enabled the company to deliver stronger cash generation peak-to-trough and supported its strong balance sheet, enabling a more shareholder-friendly approach to capital allocation.”Overall, CAT retains a ‘Moderate Buy’ from the analyst consensus, including 9 buy, 3 hold, and 2 sell reviews. Shares sell for $122 as of May 20, and the average price target of $150 suggests a 22% upside potential.View CAT Price Target & Analyst Rating Detail Deere & Co. (DE – Research Report)Nothing runs like a Deere, but investors ran away from Deere shares after the May 17 Q2 earnings report. The manufacturer of agricultural equipment (from backyard riding mowers to giant agribusiness harvester combines, plus everything in between) missed the EPS forecast by 2%, reporting $3.52 against the expected $3.61. Despite the earnings miss, net equipment sales revenues came in just above the $10.12 billion expectation, at $10.3 billion.According to the company, however, investors should not expect to keep seeing revenue beats this year. Deere lowered guidance on 2019 net income from $3.6 billion to $3.3 billion. Company CEO Sam Allen said of the lower guidance, “Although the long-term fundamentals for our businesses remain favorable, softening conditions in the agricultural sector have led Deere to adopt a more cautious financial outlook for the year. The lower forecast is partly a result of actions we are taking to prudently manage field inventories, which will cause production levels to be below retail sales in the second half of the year.”DE shares dropped 7.5% after the earnings report.Wall Street’s analysts have also seen the weakness in DE, even those setting ‘buy’ ratings on the stock. From RBC Capital, Seth Weber (Track Record & Ratings) says of the lowered income guidance, “…the revision is not surprising in light of the U.S.-China trade tensions and bad weather.” He lowered his price target by 10%, to $175.Stanley Elliot (Track Record & Ratings), of Stifel, also notes the softness in the agribusiness sector. He says the lowered income projection is driven by “a cocktail of negative developments in terms of trade, late plantings and swine flu.” His price target, $171, suggests a 26% upside for the stock.Deere holds a ‘Moderate Buy’ rating on the analyst consensus, based on 5 buy, 4 hold, and 1 sell rating given in the past three months. The $155 average price target that indicates a 14% upside potential from the current share price of $135.View DE Price Target & Analyst Rating Detail Johnson & Johnson (JNJ – Research Report)Consumer health care companies, emphasizing the everyday items that everyone needs no matter the state of the economy, are among the stocks usually seen as ‘recession proof.’ This doesn’t mean that they won’t drop when the market drops; rather, it means that they’ll experience less volatility. You can expect these defensive stocks to outperform when the major indexes fall or make slow gains, but they’ll also tend to lag a bit when the markets see a sharp rise.Johnson & Johnson is a classic case. JNJ released its Q1 earnings, missing the EPS by 2 cents, on April 16. Since then, the stock has slipped, risen, and slipped again, and is flat overall. On a longer-term view, JNJ is up 7.3% year-to-date and 11.4% over the past 12 months. The S&P 500, for April, is down over 2%, and in the last 12 months is only up 4%.Outperforming market slips is not JNJ’s only defensive attribute. The stock pays out a regular dividend, currently 95 cents per quarter for a 2.75% annual yield. The company has made a policy of steady, if modest, dividend increases, dating back to the early 1990s.The analysts, of course, have taken note of JNJ’s dependability in delivering profits and rewarding shareholders. Raymond James analyst Jayson Bedford (Track Record & Ratings), just after the earnings report, raised his price target to $147 (for a 6% upside), and said, “Growth was still much better than expected, which gives us more confidence in our estimates.”More recently, five-start analyst Joanne Wuensch (Track Record & Ratings) of BMO Capital, noted JNJ’s attraction in a down market. In her note on the stock, she said, “J&J's discipline to acquire and divest assets in its health care portfolio, its pristine balance sheet and its high dividend yield make the stock a strong defensive choice.” Her price target, $157, suggests an upside potential of 13%.JNJ maintains a ‘Moderate Buy’ analyst consensus rating, based on 6 buys and 5 holds given in the past three months. Shares sell for $138; the average price target of $148 indicates a modest upside potential of 7%.View JNJ Price Target & Analyst Rating Detail Enjoy Research Reports on the Stocks in this Article:Caterpillar, Inc. (CAT) Research ReportDeere & Co. (DE) Research ReportJohnson & Johnson (JNJ) Research Report
This includes presentations at the EASL International Liver Congress in April from preclinical long-term data from the previous-generation AAT as well as interim results of JNJ-3989 (ARO-HBV) among 40 patients at 24+ weeks follow-up in their ongoing Phase 1/2 study. The JNJ-3989 Phase 1/2 study (chronic hepatitis B) continues and was recently expanded to include a triple combination cohort (cohort 12), which along with JNJ-3989, will include additional undisclosed agents chosen by Janssen. Management indicated that this triple combination cohort could generate data relatively quickly – which will be one of several near-term development-related announcements that we anticipate.
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
With the launch of his new company, Miraki Innovation, Velis hopes to expand his reach in medtech, founding more companies in healthcare diagnostics, infectious disease and robotics that will follow Auris’ lead.
PENJERLA/NEW DELHI, India (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.
PENJERLA/NEW DELHI, India May 19 (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.
Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.
Here's what management wants investors to know about the future of the company's pharmaceutical segment.
Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.
The U.S. FBI is investigating corporate giants Johnson & Johnson, Siemens AG, General Electric Co and Philips for allegedly paying kickbacks as part of a scheme involving medical equipment sales in Brazil, two Brazilian investigators have told Reuters. Brazilian prosecutors suspect the companies channelled illegal payoffs to government officials to secure contracts with public health programs across the South American country over the past two decades. Brazilian authorities say more than 20 companies may have been part of a "cartel" that paid bribes and charged the government inflated prices for medical gear such as magnetic resonance imaging machines and prosthetics.
The View from New Brunswick Johnson & Johnson is continuously pioneering new techniques and concepts for a brighter, healthier future. What the landscape looks like from atop one of the world's biggest and most admired health care companies. CNBC's Meg Tirrell concludes the day with J&J chairman and CEO Alex Gorsky.